Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Lenalidomide (LEN) is a key treatment for multiple myeloma (MM).
• Primary resistance to LEN occurs in some patients, with underlying mechanisms not fully understood.
• Identifying resistance mechanisms is crucial for improving MM therapy.

Purpose of the Study:

• To identify protein expression profiles linked to primary lenalidomide resistance in MM.
• To elucidate the role of CSN5 in lenalidomide resistance.
• To explore the molecular pathways involved in lenalidomide resistance.

Main Methods:

• Combined lenalidomide sensitivity assays with proteomics data from 15 MM cell lines.
• Investigated protein degradation pathways, including ubiquitination and the ubiquitin-proteasome system.
• Analyzed the interaction of CSN5 with cullin-RING ligase complexes.

Main Results:

• CSN5 expression was significantly lower in lenalidomide-resistant MM cell lines compared to sensitive ones.
• CSN5 is degraded through the cullin-RING ubiquitin ligase (CRL)-mediated ubiquitin-proteasome pathway via ubiquitination at lysine 194.
• Reduced CSN5 expression disrupts the CRL4A ubiquitination cycle, inhibiting lenalidomide-induced degradation of IKZF1 and IKZF3.

Conclusions:

• Lower CSN5 expression represents a novel mechanism of primary lenalidomide resistance in multiple myeloma.
• The findings highlight the importance of the CSN5-CRL4A-IKZF axis in lenalidomide sensitivity.
• This research may pave the way for developing strategies to overcome lenalidomide resistance in MM patients.